Display options
Cite
Rao X, De Boer RJ, van Baarle D, et al. Complementarity of Binding Motifs is a General Property of HLA-A and HLA-B Molecules and Does Not Seem to Effect HLA Haplotype Composition. Front Immunol. 2013;4:374doi: 10.3389/fimmu.2013.00374.
Rao, X., De Boer, R. J., van Baarle, D., Maiers, M., & Kesmir, C. (2013). Complementarity of Binding Motifs is a General Property of HLA-A and HLA-B Molecules and Does Not Seem to Effect HLA Haplotype Composition. Frontiers in immunology, 4374. https://doi.org/10.3389/fimmu.2013.00374
Rao, Xiangyu, et al. "Complementarity of Binding Motifs is a General Property of HLA-A and HLA-B Molecules and Does Not Seem to Effect HLA Haplotype Composition." Frontiers in immunology vol. 4 (2013): 374. doi: https://doi.org/10.3389/fimmu.2013.00374
Rao X, De Boer RJ, van Baarle D, Maiers M, Kesmir C. Complementarity of Binding Motifs is a General Property of HLA-A and HLA-B Molecules and Does Not Seem to Effect HLA Haplotype Composition. Front Immunol. 2013 Nov 14;4:374. doi: 10.3389/fimmu.2013.00374. eCollection 2013. PMID: 24294213; PMCID: PMC3827838.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2013 Nov 14;4:374. doi: 10.3389/fimmu.2013.00374. eCollection 2013.

Complementarity of Binding Motifs is a General Property of HLA-A and HLA-B Molecules and Does Not Seem to Effect HLA Haplotype Composition.

Frontiers in immunology

Xiangyu Rao, Rob J De Boer, Debbie van Baarle, Martin Maiers, Can Kesmir

Affiliations

  1. Theoretical Biology and Bioinformatics, Utrecht University , Utrecht , Netherlands.

PMID: 24294213 PMCID: PMC3827838 DOI: 10.3389/fimmu.2013.00374

Abstract

Different human leukocyte antigen (HLA) haplotypes (i.e., the specific combinations of HLA-A, -B, -DR alleles inherited together from one parent) are observed in different frequencies in human populations. Some haplotypes, like HLA-A1-B8, are very frequent, reaching up to 10% in the Caucasian population, while others are very rare. Numerous studies have identified associations between HLA haplotypes and diseases, and differences in haplotype frequencies can in part be explained by these associations: the stronger the association with a severe (autoimmune) disease, the lower the expected HLA haplotype frequency. The peptide repertoires of the HLA molecules composing a haplotype can also influence the frequency of a haplotype. For example, it would seem advantageous to have HLA molecules with non-overlapping binding specificities within a haplotype, as individuals expressing such an haplotype would present a diverse set of peptides from viruses and pathogenic bacteria on the cell surface. To test this hypothesis, we collect the proteome data from a set of common viruses, and estimate the total ligand repertoire of HLA class I haplotypes (HLA-A-B) using in silico predictions. We compare the size of these repertoires to the HLA haplotype frequencies reported in the National Marrow Donor Program (NMDP). We find that in most HLA-A and HLA-B pairs have fairly distinct binding motifs, and that the observed haplotypes do not contain HLA-A and -B molecules with more distinct binding motifs than random HLA-A and HLA-B pairs. In addition, the population frequency of a haplotype is not correlated to the distinctness of its HLA-A and HLA-B peptide binding motifs. These results suggest that there is a not a strong selection pressure on the haplotype level favoring haplotypes having HLA molecules with distinct binding motifs, which would result the largest possible presented peptide repertoires in the context of infectious diseases.

Keywords: HLA antigens; bioinformatics; computational biology; genetic; haplotypes; peptide binding; selection

References

  1. Tissue Antigens. 2003 May;61(5):403-7 - PubMed
  2. J Immunol. 1991 Oct 15;147(8):2663-9 - PubMed
  3. PLoS One. 2007 Aug 29;2(8):e796 - PubMed
  4. Immunogenetics. 2004 Feb;55(11):725-31 - PubMed
  5. Science. 1999 Mar 12;283(5408):1748-52 - PubMed
  6. Hum Immunol. 2007 Sep;68(9):779-88 - PubMed
  7. Trends Neurosci. 2006 Feb;29(2):100-7 - PubMed
  8. PLoS Comput Biol. 2009 Mar;5(3):e1000327 - PubMed
  9. Crit Rev Immunol. 1997;17(2):179-224 - PubMed
  10. Cancer Res. 2008 May 1;68(9):3532-9 - PubMed
  11. Immunology. 2010 Apr;129(4):496-505 - PubMed
  12. Int J Immunogenet. 2008 Dec;35(6):427-32 - PubMed
  13. Nature. 2000 Feb 17;403(6771):723-4 - PubMed
  14. Nat Genet. 2001 Aug;28(4):361-4 - PubMed
  15. Immunogenetics. 2009 Jan;61(1):1-13 - PubMed
  16. Eur J Immunol. 2007 Sep;37(9):2419-33 - PubMed
  17. Protein Sci. 2003 May;12(5):1007-17 - PubMed
  18. Genomics. 2006 May;87(5):561-71 - PubMed
  19. Annu Rev Med. 2005;56:303-20 - PubMed
  20. Immunogenetics. 2011 Nov;63(11):691-701 - PubMed
  21. Hum Immunol. 2007 Dec;68(12):950-8 - PubMed
  22. BMC Bioinformatics. 2008 Jan 29;9:68 - PubMed
  23. Tissue Antigens. 2003 Nov;62(5):378-84 - PubMed
  24. Am J Hum Genet. 1995 Mar;56(3):799-810 - PubMed
  25. Tissue Antigens. 2010 Dec;76(6):459-66 - PubMed
  26. Mol Biol Evol. 1995 Sep;12(5):921-7 - PubMed
  27. J Virol. 2007 Feb;81(3):1412-23 - PubMed
  28. J Immunol. 1992 Jan 1;148(1):249-58 - PubMed
  29. Genet Epidemiol. 2004 Dec;27(4):334-47 - PubMed
  30. Tissue Antigens. 2009 Aug;74(2):156-63 - PubMed
  31. Immunol Rev. 1999 Feb;167:245-56 - PubMed

Publication Types